An Exploratory Pharmacogenomic Study of Monotherapy Erbitux in Subjects With Metastic Colorectal Cancer
| Status: | Completed |
|---|---|
| Conditions: | Colorectal Cancer, Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 4/21/2016 |
| Start Date: | December 2003 |
| End Date: | February 2006 |
The purpose of this study is to predict response to Erbitux as a single agent in patients
with metastatic colon cancer
with metastatic colon cancer
Inclusion Criteria:
- Measurable disease Tumor available for biopsies. Life expectancy of at least 3
months.
Exclusion Criteria:
- Known or documented brain metastases prior to Cetuximab therapy.
We found this trial at
13
sites
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials